[Chronic lymphoid leukemia: a single disease or 2 distinct diseases?]

Area of Science:

• Hematology
• Oncology
• Immunology

Context:

• Chronic Lymphocytic Leukemia (CLL) is a heterogeneous B-cell malignancy with variable clinical presentations and prognoses.
• Understanding the underlying biology of CLL is crucial for accurate diagnosis and effective treatment strategies.

Purpose:

• To explore the heterogeneity of Chronic Lymphocytic Leukemia (CLL) and identify key prognostic markers.
• To investigate potential distinct subtypes of CLL based on cell differentiation and genetic mutations.

Summary:

• CLL arises from malignant B cells, presenting with diverse clinical courses, from indolent to aggressive.
• Biologic markers, including cytogenetic abnormalities (e.g., 11q deletions), CD38 expression, and immunoglobulin heavy chain gene mutations, aid in predicting CLL prognosis.
• While mutated immunoglobulin genes suggest a better prognosis and unmutated genes a poorer one, shared morphology and gene expression profiles indicate a common origin for all CLL cases.

Impact:

• Advances in understanding CLL heterogeneity and prognostic markers can lead to more personalized treatment approaches.
• Identifying distinct CLL subtypes may facilitate the development of targeted therapies.
• This research contributes to a deeper comprehension of B-cell malignant transformation and CLL pathogenesis.